Correction to: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.